<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PPAR Res</journal-id><journal-id journal-id-type="publisher-id">PPAR</journal-id><journal-title>PPAR Research</journal-title><issn pub-type="ppub">1687-4757</issn><issn pub-type="epub">1687-4765</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19266045</article-id><article-id pub-id-type="pmc">2649533</article-id><article-id pub-id-type="doi">10.1155/2009/369602</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Differences in Transcriptional Activation by the Two Allelic (L162V Polymorphic) Variants of PPAR<italic>&#x003b1;</italic> after Omega-3 Fatty Acids Treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rudkowska</surname><given-names>Iwona</given-names></name><xref ref-type="aff" rid="I1"><sup>1,2,3</sup></xref><xref ref-type="aff" rid="I2"/><xref ref-type="aff" rid="I3"/></contrib><contrib contrib-type="author"><name><surname>Verreault</surname><given-names>M&#x000e9;lanie</given-names></name><xref ref-type="aff" rid="I4"><sup>4,5</sup></xref><xref ref-type="aff" rid="I5"/></contrib><contrib contrib-type="author"><name><surname>Barbier</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="I4"><sup>4,5</sup></xref><xref ref-type="aff" rid="I5"/></contrib><contrib contrib-type="author"><name><surname>Vohl</surname><given-names>Marie-Claude</given-names></name><xref ref-type="aff" rid="I1"><sup>1,2,3</sup></xref><xref ref-type="aff" rid="I2"/><xref ref-type="aff" rid="I3"/><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Lipid Research Center, CHUL Research Center, QC, Canada G1V 4G2</aff><aff id="I2"><sup>2</sup>Department of Food Science and Nutrition, Laval University, QC, Canada G1V 0A6</aff><aff id="I3"><sup>3</sup>Nutraceuticals and Functional Foods Institute (INAF), Laval University, QC, Canada G1V 0A6</aff><aff id="I4"><sup>4</sup>Laboratory of Molecular Pharmacology, Oncology and Genomic Research Center, CHUL Research Center, QC, Canada G1V 4G2</aff><aff id="I5"><sup>5</sup>Faculty of Pharmacy, Laval University, QC, Canada G1V 0A6</aff><author-notes><corresp id="cor1">*Marie-Claude Vohl: <email>marie-claude.vohl@crchul.ulaval.ca</email></corresp><fn fn-type="other"><p>Recommended by Mostafa Badr</p></fn></author-notes><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>25</day><month>2</month><year>2009</year></pub-date><volume>2009</volume><elocation-id>369602</elocation-id><history><date date-type="received"><day>22</day><month>8</month><year>2008</year></date><date date-type="rev-recd"><day>26</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Iwona Rudkowska et al.</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Omega-3 fatty acids (FAs) have the potential to regulate geneexpression via the peroxisome proliferator-activated receptor <italic>&#x003b1;</italic> (PPAR<italic>&#x003b1;</italic>);                    therefore, genetic variations in this gene may                    impact itstranscriptional activity on target genes. It is hypothesized thatthe transcriptional activity by wild-type L162-PPAR<italic>&#x003b1;</italic> is enhancedto a greater extent than the mutated variant (V162-PPAR<italic>&#x003b1;</italic>) in thepresence of eicosapentaenoic acid (EPA), docosahexaenoic acid(DHA) or a mixture of EPA:DHA. To examine the functionaldifference of the two allelic variants on receptor activity,transient co-transfections were performed in human hepatoma HepG2cells activated with EPA, DHA and EPA:DHA mixtures. Resultsindicate that the addition of EPA or DHA demonstrate potential toincrease the transcriptional activity by PPAR<italic>&#x003b1;</italic> with respect tobasal level in both variants. Yet, the EPA:DHA mixtures enhancedthe transcriptional activity to a greater extent than individualFAs indicating possible additive effects of EPA and DHA.Additionally, the V162 allelic form of PPAR<italic>&#x003b1;</italic> demonstratedconsistently lower transcriptional activation when incubated withEPA, DHA or EPA:DHA mixtures than, the wild-type variant. Inconclusion, both allelic variants of the PPAR<italic>&#x003b1;</italic> L162V are activatedby omega-3 FAs; however, the V162 allelic form displays a lowertranscriptional activity than the wild-type variant.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. Introduction</title><p>Higher intake of long-chain n-3fatty acids (FAs) eicosapentaenoic acid (EPA) anddocosahexaenoic acid (DHA) has been recommended to decrease plasma triglyceride (TG) levels. Conventionally, the mechanism ofaction after n-3 FAs intake focused on plasma membrane fluidity; however,recently the emphasis shifted to regulation of gene expression [<xref ref-type="bibr" rid="B1">1</xref>]. Inparticular, FAs and their derivatives are physiological ligands of peroxisomeproliferator-activated receptor <italic>&#x003b1;</italic> (PPAR<italic>&#x003b1;</italic>). As such they activate the PPAR<italic>&#x003b1;</italic>-retinoid X receptor (RXR) heterodimer-dependent gene transcription bybinding to the peroxisome proliferator response elements (PPRE) in the promoterregion of target genes [<xref ref-type="bibr" rid="B2">2</xref>]. Target genes include lipoprotein lipase (LPL) involved inplasma TG clearance [<xref ref-type="bibr" rid="B2">2</xref>]. </p><p>Severalpolymorphisms within the PPAR<italic>&#x003b1;</italic> gene and the encodedproteins have been identified including L162Vand V227A, which are the most common PPAR<italic>&#x003b1;</italic> polymorphisms reported [<xref ref-type="bibr" rid="B3">3</xref>]. Of particular interest, the PPAR<italic>&#x003b1;</italic>				L162V polymorphism hasbeen associated with obesity indices and plasma lipid levels in numerous studies [<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B8">8</xref>]. Additionally, Robitaille et al. in 2004 found that the interactionbetween the PPAR<italic>&#x003b1;</italic>				L162V polymorphism and fat intakeestimated from a food frequency questionnaire (FFQ) explains a significantpercentage of the variance observed in waist girth in a sample of 260French-Canadians [<xref ref-type="bibr" rid="B9">9</xref>].  Tai et al. in 2005 [<xref ref-type="bibr" rid="B10">10</xref>] also establishedthat the effect of the PPAR<italic>&#x003b1;</italic>				L162V polymorphism on plasma TG and apolipoprotein (apo)-CIIIconcentrations depends on the dietary polyunsaturated FA (PUFA), with a high intake triggeringlower TG in carriers of the V162-PPAR<italic>&#x003b1;</italic> variant.  Finally, Paradiset al. in 2002 [<xref ref-type="bibr" rid="B11">11</xref>] demonstrated that the interindividual variations in totalcholesterol, apo A-I, and cholesterol concentrations in small low-densitylipoprotein (LDL) particles observed after modification of thepolyunsaturated/saturated FA ratio of the diet is partly attributable to the PPAR<italic>&#x003b1;</italic>				L162V polymorphism. Clearly, both epidemiological andinterventional studies demonstrate a relation between the PPAR<italic>&#x003b1;</italic> L162V polymorphisms, metabolicparameters, and FAs intake; yet, only two functional studies examined thereceptor activity of the L162V polymorphic variantsactivated with synthetic agonists-fibrates [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B12">12</xref>]. It was demonstrated that the effect of the L162V polymorphic variants on the transcriptional activationwas associated with the concentration of the ligand to which it is exposed[<xref ref-type="bibr" rid="B12">12</xref>].</p><p>For that reason, the aimof this functional study was to determine whether the transcriptional activity by the wild-typevariant, L162-PPAR<italic>&#x003b1;</italic>,is enhanced in the presence of natural PPAR<italic>&#x003b1;</italic>agonists-omega-3 FAs, mimicking the action of synthetic PPAR<italic>&#x003b1;</italic>agonists, comparatively to the variant, V162-PPAR<italic>&#x003b1;</italic>.</p></sec><sec sec-type="section" id="sec2"><title>2. Laboratory Methods</title><sec id="subsec2.1"><title>2.1. Plasmid Construction</title><p>The wild-type L162-PPAR expressionplasmid (pSG5-hPPAR<italic>&#x003b1;</italic> vector) was a kind gift from Pr. B. Staels (Unit&#x000e9;INSERM 545, Institut Pasteur de Lille, France). The pSG5-mRXR<italic>&#x003b1;</italic>plasmid was described previously [<xref ref-type="bibr" rid="B13">13</xref>]. The V162-PPAR<italic>&#x003b1;</italic>expression plasmid was derived from the wild-type, through site-directedmutagenesis (QuickChange site-directed mutagenesis kit, Stratagene, La Jolla, Calif,USA) using the 						5&#x02032;-CGATTTCACAAGTGC<bold>G</bold>TTTCTGTCGGGATG-3&#x02032;oligonucleotide  (the nucleotide in boldface type denotes the C&#x02192;G change mutated base). Variant cDNAs weredirectly sequenced to confirm that no spurious base changes have beenintroduced during the procedure. As a response element representative of thevast variety of human PPREs, we choose the consensus artificial direct repeat(DR)1 sequence for analyzing the functional consequences of L162V variation onPPAR<italic>&#x003b1;</italic> activation by omega-3FAs. Thus, a reporter plasmid (DR1x6-PPRE)wasgenerated by cloning in front of the thymidine kinase promoter-driven luciferasereporter gene (TKpGL3 vector), sixcopies of the 						5&#x02032;-AAAACT<underline>AGGTCA</underline>A<underline>AGGTCA</underline>CGG-3&#x02032;sequence where underlined nucleotides correspond to the direct repeat of theAGGTCA hexamer.</p></sec><sec id="subsec2.2"><title>2.2. Transient Transfection and n-3 Fatty Acids Activation</title><p>Humanhepatoma HepG2 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM)supplemented by 10% fetal bovine serum (FBS), 1% of streptomycin penicillin, 1%of sodium pyruvate and 1% of glutamine. HepG2 cells were plated at a density of75 &#x000d7; 10<sup>3</sup> cells/well of 24-well plates which were then transfected using the ExGenreagent (Invitrogen, Burlington, Canada) with 50 ng of the DR1x6-PPRE reporter plasmid, 10 ng of the PPAR<italic>&#x003b1;</italic> (wild-type or mutant) and <italic>RXR</italic> expression plasmids and 30 ng of the pRL-NULL expression vector (Promega) for 6 hours 37&#x000b0;C. All samples were complemented with pBS-SK+plasmid (Stratagene) to an identical amount (500 ng/well). Similar experiments were performed with anegative control consisting of the empty TK-pGL3-basic plasmid (Promega). Aftertransfection, cells were cultured in DMEM supplemented by 0.2% FBS for 24 hours to strengthencell membrane before addition of FAs. Afterwards, cells were transactivated for 24 hours in absence orpresence of omega-3 FAs in concentrations varying between 1&#x02013;15 <italic>&#x003bc;</italic>M to reflectbiological plasma or red blood cells concentration of FAs [<xref ref-type="bibr" rid="B14">14</xref>]. Cells were treated with eithersolvent (dimethyl sulfoxide (DMSO), 0.01% final concentration), or treatments of EPA and/or DHA (Sigma-Aldrich,Oakville, ON, Canada). Briefly, pure EPA or DHA was dissolved by serial dilution to 1, 5, 10,and 15 <italic>&#x003bc;</italic>M in DMSO. For mixtures of 5:5, 15:5, and 5:15 <italic>&#x003bc;</italic>M EPA:DHA, the dissolved individual omega-3 FAs at appropriate concentrations weremixed together. The luciferaseactivity was quantified with a luminometer (Bertholus, LB956V) and expressed asfold induction in the presence of variable doses of omega-3 FAs over control. Ciprofibrate (250 <italic>&#x003bc;</italic>M) (Sigma-Aldrich) was used as a positive control ofinduction. The assays were performed in triplicates. The experiment wasconducted in duplicate.</p></sec><sec id="subsec2.3"><title>2.3. Data Analysis</title><p>Firefly luciferase activities werenormalized with the corresponding Renilla luciferase reporter activity asinternal control. Fold induction was calculated by taking the control  DMSO (Sigma-Aldrich) as baseline.</p></sec></sec><sec sec-type="section" id="sec3"><title>3. Results</title><p>Transient transfection assays inhuman hepatoma HepG2 cells were done to compare L162-PPAR<italic>&#x003b1;</italic> to V162-PPAR<italic>&#x003b1;</italic> transcriptional activity. In sum, twoindependent transients'transfection assays were performed with similar results for transcriptionalactivity. The V162-PPAR<italic>&#x003b1;</italic> variant showed similar basal transcriptional activity after treatmentwith DMSO compared with L162-PPAR<italic>&#x003b1;</italic> on the DR1x6-PPRE. Forpositive control, the presence of the PPAR synthetic ligand, ciprofibrate,showed enhanced transactivation activity in V162-PPAR<italic>&#x003b1;</italic>compared with L162-PPAR<italic>&#x003b1;</italic>(<xref ref-type="fig" rid="fig1">Figure 1</xref>). Most importantly, the results from this functional study demonstratethat increase in activity in the V162-PPAR<italic>&#x003b1;</italic> variant did not reach the samelevel of extent of transcriptional activity as the L162-PPAR<italic>&#x003b1;</italic> variant in all replicates and doses of omega-3FAs.</p><p>In more details, the addition of 5 and 15 <italic>&#x003bc;</italic>M EPA resultedin an increased in activity with respect to basal level of EPA of 1 <italic>&#x003bc;</italic>M in L162-PPAR<italic>&#x003b1;</italic> variant, yet only 15 <italic>&#x003bc;</italic>M EPA resulted in aslight increase in transcriptional rate compared to DMSO (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In the same way, theaddition of 5, 10, and 15 <italic>&#x003bc;</italic>M EPA resulted in an higher activity, with respectto basal level in V162-PPAR<italic>&#x003b1;</italic> variant (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Nevertheless, transcriptional activity by the L162-PPAR<italic>&#x003b1;</italic> variant compared to V162-PPAR<italic>&#x003b1;</italic> variant was 9%,11%, 4% and 6% consistentlygreater with 1, 5, 10, and 15 <italic>&#x003bc;</italic>M of EPA (<xref ref-type="fig" rid="fig1">Figure 1</xref>)representing functional differences between the variants.</p><p>Similarly, the additionof DHA enhanced transcriptional activity at most concentrations in both the L162-PPAR<italic>&#x003b1;</italic> and V162-PPAR<italic>&#x003b1;</italic> variant compared to basal level ofDHA (<xref ref-type="fig" rid="fig1">Figure 1</xref>). However, only 10 or 15 <italic>&#x003bc;</italic>M of DHA in the L162-PPAR<italic>&#x003b1;</italic> increased activity compared to DMSO. Likewise,the addition of 1, 5, 10, or 15 <italic>&#x003bc;</italic>M of DHA increased to a greater extent thetranscriptional activity by the L162-PPAR<italic>&#x003b1;</italic> variant compared to the V162-PPAR<italic>&#x003b1;</italic> variant (17%, 5%, 15%, and 3%;resp.) (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>In addition, EPA:DHA mixtures tested showed a markedincrease in transcriptional activity that was higher with respect to individual FAtranscriptional activity or basal activity (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Again in the V162-PPAR<italic>&#x003b1;</italic> variant, the ratios of EPA:DHAincreased the receptor activity but to a lesser degree than in L162-PPAR<italic>&#x003b1;</italic> (<xref ref-type="fig" rid="fig1">Figure1</xref>). The disparities in transcriptional activity between the L162-PPAR<italic>&#x003b1;</italic> and V162-PPAR<italic>&#x003b1;</italic> variants were even more important:24%, 28%, and 17% for 5:5, 5:15 and 15:5 <italic>&#x003bc;</italic>M EPA:DHA ratios,respectively. Overall, even if the individual FAs show a smallertranscriptional activity by PPAR<italic>&#x003b1;</italic> with a larger standard deviation,this transcriptional activity is consistently lower in the V162-PPAR<italic>&#x003b1;</italic> than L162-PPAR<italic>&#x003b1;</italic>. Further, this information is supported by theresults of the mixtures of EPA:DHA, where there is clearly an increasedtranscriptional activity and this effect is of lesser magnitude in V162-PPAR<italic>&#x003b1;</italic> than L162-PPAR<italic>&#x003b1;</italic>.</p></sec><sec sec-type="section" id="sec4"><title>4. Discussion</title><p>The present study represents the first examination of the variation intranscriptional activity afteromega-3 FA activation in the L162V polymorphic variant. Overall,the use of natural PPAR<italic>&#x003b1;</italic> agonists, such as omega-3 FAs, mayinfluence the activation of PPAR<italic>&#x003b1;</italic> at higher doses. Nevertheless, differences exist in the rates of transcriptional activityby the V162-PPAR<italic>&#x003b1;</italic> and the L162-PPAR<italic>&#x003b1;</italic> variant ofthe PPAR<italic>&#x003b1;</italic>				L162V polymorphism. In addition, the additive effects of EPA and DHA mixtures ontranscription rates may reveal supplementary benefits compared to theindividual omega-3 FAs.</p><p>The results clearlyreveal that the V162-PPAR<italic>&#x003b1;</italic> has lower transcriptional activity than theL162-PPAR<italic>&#x003b1;</italic>. Previous research has demonstratedthe impact of PPAR<italic>&#x003b1;</italic> on the clearance of TG-rich lipoproteins in humansafter treatment with PPAR<italic>&#x003b1;</italic> agonist, fibrates [<xref ref-type="bibr" rid="B15">15</xref>]. The plasma TG loweringeffect of fibrates can be duplicated in animal studies [<xref ref-type="bibr" rid="B16">16</xref>]. In contrast,plasma TGs are elevated in animals lacking PPAR<italic>&#x003b1;</italic> [<xref ref-type="bibr" rid="B17">17</xref>]. This datasuggest that PPAR<italic>&#x003b1;</italic> adjusts LPL-dependent TG lypolysis by alteringexpression of pro- and antilipolytic factors [<xref ref-type="bibr" rid="B18">18</xref>]. Thus, the current results demonstrate thatindividuals carrying a V162-PPAR<italic>&#x003b1;</italic> variant may potentially have elevated TG levels due to lowertranscription rate of target genes, such as <italic>LPL</italic>. These in vitro results supportthe numerous human studies in which the PPAR<italic>&#x003b1;</italic>				L162V polymorphism exhibited associations with totalcholesterol, LDL-cholesterol, apo B, TG, and high-density lipoproteins (HDL)-cholesterol [<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B9">9</xref>].  In general, from the current and previoushuman studies, the V162 allele appears to be associated with a more harmfullipid profile potentially due to a lower transcription rate of target geneswith PPREs.</p><p>The improve transactivation of both allelic variants following anomega-3 FA activation reveals the importance of stratifyingindividuals according to their dietary fat intakes including omega-3 FA todemonstrate the influence of PPAR<italic>&#x003b1;</italic>				L162V polymorphism on lipid parameters and other metabolicfactors. Since themutation is located in the DNA binding domain, this single nucleotidepolymorphism is thought to have an impact on the receptor's ability to bind DNA[<xref ref-type="bibr" rid="B12">12</xref>]. While receptors coregulators (i.e., coactivators and corepressors)generally interact with the ligand binding domain of nuclear receptors [<xref ref-type="bibr" rid="B19">19</xref>], wecannot exclude that the L162V amino acid substitution affects the PPAR<italic>&#x003b1;</italic>'s ability to adequately separate from cytoplasmic corepressor, transitto the nuclei and/or recruit coactivators, as it was demonstrated for the V227Avariant of this receptor [<xref ref-type="bibr" rid="B20">20</xref>]. To the best of our knowledge functional studieshave never been performed for the PPAR<italic>&#x003b1;</italic>				L162V mutation, and the mechanisms at the basis ofdifferential omega-3 FAs-dependent activationof the wild-type and mutated receptors remain to beelucidated. Yet, it appears that the V162-PPAR<italic>&#x003b1;</italic>has the potential to reach comparable transcription rates as L162-PPAR<italic>&#x003b1;</italic> withhigher intakes of individual or mixtures of omega-3 FAs. Therefore,the influence of the L162V polymorphic variant may be more apparent inindividuals who consume a lower intake of omega-3 FAs. These results are inaccordance with previous human studies [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B21">21</xref>] which examined the effect of the PPAR<italic>&#x003b1;</italic>				L162V polymorphism in relation to diet.  Theseprevious researchers determinedthat a high intake of dietary PUFA can lower TG in carriers of the V162-PPAR<italic>&#x003b1;</italic> allele [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>] due to higher n-3 FA intakes that may lead to increased activation of PPAR<italic>&#x003b1;</italic>. Finally, a recent study by Caron-Dorval et al. in 2008 [<xref ref-type="bibr" rid="B21">21</xref>] demonstratedthat plasma TG levels decreased similarly between a group of 28 young men withor without the L162V polymorphismafter an intense omega-3 FA supplementation for 4 weeks. These results confirmthat dietary modifications including higher amounts of EPA and DHA, whichactivate PPARs to a greater level, may be an effective method in reducingmetabolic risk in those with high-risk allele, such as V162. However, thispoint requires further investigation to ascertain a precise nutritionalrecommendation.</p><p>Anadditional purpose of this study was to determine whether EPA, DHA, andcombinations of EPA:DHA have differential roles in transcriptional activity. Most studies regarding the effectsof n-3 PUFA on blood lipids were conducted with fish oils that containa mixture of EPA and DHA [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>]. Yet, a number of studies have beenconducted with EPA and DHA individually. In vitro [<xref ref-type="bibr" rid="B24">24</xref>] and animal [<xref ref-type="bibr" rid="B25">25</xref>&#x02013;<xref ref-type="bibr" rid="B28">28</xref>] studies suggest that EPA rather than DHA may be a hypotriglyceridemic agent. However, divergent findings have been reported in human studies [<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>]. Results from the current study with individual FAs indicate that a higher doseof either EPA or DHA can increase transcriptional rate of target genes. However, our results demonstrated that DHA may have a slightly highertranscriptional activity than EPA. A recent study bySanderson et al. in 2008 [<xref ref-type="bibr" rid="B31">31</xref>] showed that DHA behavedas a highly potent inducer of PPAR<italic>&#x003b1;</italic> dependent gene expressioncompared to other FAs, although they did not examine the effects of EPA ormixtures of these FAs. On the other hand, investigators who examined theeffects of oleic acid, EPA, and DHA on intestinal gene expression in miceidentified 19, 46, and 41 genes, respectively, that were activated with thesefatty acids versus 74 genes with the PPAR<italic>&#x003b1;</italic>agonist [<xref ref-type="bibr" rid="B32">32</xref>]. In addition in the current study, all tested concentrations of combination of EPA and DHA induced slightly higher transcription rates than individual FAs. However, it still remains unclear whether EPA and DHA have similar TGlowering potential. Further studies are needed todetermine whether EPA and DHA in combination, as they are foundnaturally in fish oils, have an additive effects on gene expressionrates; hence, potentially reducing TG concentrations to a greater extent thanindividual FAs.</p><p>In conclusion, theseresults indicate that the V162-PPAR<italic>&#x003b1;</italic> variant has lower transcriptionalactivity than L162-PPAR<italic>&#x003b1;</italic> variant in responseto omega-3 FAs; therefore, clearly demonstrating that a nutrient-geneinteraction exists between PPAR<italic>&#x003b1;</italic>				L162V polymorphismand omega-3 FAs. Further studies are needed toconfirm whether this difference in transcriptional activity by PPAR<italic>&#x003b1;</italic> is translated into differences in geneexpression levels of physiological target genes. Overall, the functional understanding of omega-3 FAs in relation to PPAR<italic>&#x003b1;</italic>				L162V genotypes may allowmore targeted individualized dietary advice to maximising the benefit gained bythe individual.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supportedby  Grant no. MOP-200609 from theCanadian Institutes of Health Research (CIHR). Authors thank Pr. B. Staels forproviding the pSG5-hPPAR construct.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kliewer</surname><given-names>SA</given-names></name><name><surname>Sundseth</surname><given-names>SS</given-names></name><name><surname>Jones</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors <italic>&#x003b1;</italic> and <italic>&#x003b3;</italic></article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1997</year><volume>94</volume><issue>9</issue><fpage>4318</fpage><lpage>4323</lpage><pub-id pub-id-type="pmid">9113987</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kersten</surname><given-names>S</given-names></name></person-group><article-title>Peroxisome proliferator activated receptors and lipoprotein metabolism</article-title><source><italic>PPAR Research</italic></source><year>2008</year><volume>2008</volume><fpage>11 pages</fpage><comment>Article ID 132960.</comment></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yong</surname><given-names>EL</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>MH</given-names></name></person-group><article-title>Single gene contributions: genetic variants of peroxisome proliferator-activated receptor (isoforms <italic>&#x003b1;</italic>, <italic>&#x003b2;</italic>/<italic>&#x003b4;</italic> and <italic>&#x003b3;</italic>) and mechanisms of dyslipidemias</article-title><source><italic>Current Opinion in Lipidology</italic></source><year>2008</year><volume>19</volume><issue>2</issue><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">18388689</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flavell</surname><given-names>DM</given-names></name><name><surname>Pineda Torra</surname><given-names>I</given-names></name><name><surname>Jamshidi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Variation in the PPAR<italic>&#x003b1;</italic> gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects</article-title><source><italic>Diabetologia</italic></source><year>2000</year><volume>43</volume><issue>5</issue><fpage>673</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">10855543</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>ES</given-names></name><name><surname>Demissie</surname><given-names>S</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2002</year><volume>22</volume><issue>5</issue><fpage>805</fpage><lpage>810</lpage></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Ordovas</surname><given-names>JM</given-names></name><name><surname>Delgado-Lista</surname><given-names>J</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b1;</italic> polymorphisms and postprandial lipemia in healthy men</article-title><source><italic>Journal of Lipid Research</italic></source><year>2007</year><volume>48</volume><issue>6</issue><fpage>1402</fpage><lpage>1408</lpage><pub-id pub-id-type="pmid">17363837</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uthurralt</surname><given-names>J</given-names></name><name><surname>Gordish-Dressman</surname><given-names>H</given-names></name><name><surname>Bradbury</surname><given-names>M</given-names></name><etal/></person-group><article-title>PPAR<italic>&#x003b1;</italic> L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males</article-title><source><italic>BMC Medical Genetics</italic></source><year>2007</year><volume>8, article 55</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">17227582</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spars&#x000f8;</surname><given-names>T</given-names></name><name><surname>Hussain</surname><given-names>MS</given-names></name><name><surname>Andersen</surname><given-names>G</given-names></name><etal/></person-group><article-title>Relationships between the functional PPAR<italic>&#x003b1;</italic> Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people</article-title><source><italic>Molecular Genetics and Metabolism</italic></source><year>2007</year><volume>90</volume><issue>2</issue><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">17129741</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robitaille</surname><given-names>J</given-names></name><name><surname>Brouillette</surname><given-names>C</given-names></name><name><surname>Houde</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association between the PPAR<italic>&#x003b1;</italic>-L162V polymorphism and components of the metabolic syndrome</article-title><source><italic>Journal of Human Genetics</italic></source><year>2004</year><volume>49</volume><issue>9</issue><fpage>482</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">15309680</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>ES</given-names></name><name><surname>Corella</surname><given-names>D</given-names></name><name><surname>Demissie</surname><given-names>S</given-names></name><etal/></person-group><article-title>Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study</article-title><source><italic>Journal of Nutrition</italic></source><year>2005</year><volume>135</volume><issue>3</issue><fpage>397</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">15735069</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paradis</surname><given-names>A-M</given-names></name><name><surname>Fontaine-Bisson</surname><given-names>B</given-names></name><name><surname>Boss&#x000e9;</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The peroxisome proliferator-activated receptor <italic>&#x003b1;</italic> Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men</article-title><source><italic>American Journal of Clinical Nutrition</italic></source><year>2005</year><volume>81</volume><issue>2</issue><fpage>523</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">15699244</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sapone</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>JM</given-names></name><name><surname>Sakai</surname><given-names>S</given-names></name><etal/></person-group><article-title>The human peroxisome proliferator-activated receptor <italic>&#x003b1;</italic> gene: identification and functional characterization of two natural allelic variants</article-title><source><italic>Pharmacogenetics</italic></source><year>2000</year><volume>10</volume><issue>4</issue><fpage>321</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">10862523</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vu-Dac</surname><given-names>N</given-names></name><name><surname>Schoonjans</surname><given-names>K</given-names></name><name><surname>Kosykh</surname><given-names>V</given-names></name><etal/></person-group><article-title>Retinoids increase human apolipoprotein A-II expression through activation of the retinoid X receptor but not the retinoic acid receptor</article-title><source><italic>Molecular and Cellular Biology</italic></source><year>1996</year><volume>16</volume><issue>7</issue><fpage>3350</fpage><lpage>3360</lpage><pub-id pub-id-type="pmid">8668150</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jungling</surname><given-names>E</given-names></name><name><surname>Kammermeier</surname><given-names>H</given-names></name></person-group><article-title>A one-vial method for routine extraction and quantification of free fatty acids in blood and tissue by HPLC</article-title><source><italic>Analytical Biochemistry</italic></source><year>1988</year><volume>171</volume><issue>1</issue><fpage>150</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">3407911</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>HS</given-names></name><name><surname>Williamson</surname><given-names>CM</given-names></name><name><surname>Olivecrona</surname><given-names>T</given-names></name><etal/></person-group><article-title>Postprandial lipemia, fenofibrate and coronary artery disease</article-title><source><italic>Atherosclerosis</italic></source><year>1990</year><volume>85</volume><issue>2-3</issue><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">2102083</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>JM</given-names></name><name><surname>Hennuyer</surname><given-names>N</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name><etal/></person-group><article-title>Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor <italic>&#x003b1;</italic>-deficient mice</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1997</year><volume>272</volume><issue>43</issue><fpage>27307</fpage><lpage>27312</lpage><pub-id pub-id-type="pmid">9341179</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costet</surname><given-names>P</given-names></name><name><surname>Legendre</surname><given-names>C</given-names></name><name><surname>Mor&#x000e9;</surname><given-names>J</given-names></name><name><surname>Edgar</surname><given-names>A</given-names></name><name><surname>Galtier</surname><given-names>P</given-names></name><name><surname>Pineau</surname><given-names>T</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b1;</italic>-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1998</year><volume>273</volume><issue>45</issue><fpage>29577</fpage><lpage>29585</lpage><pub-id pub-id-type="pmid">9792666</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duval</surname><given-names>C</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name><name><surname>Kersten</surname><given-names>S</given-names></name></person-group><article-title>PPAR<italic>&#x003b1;</italic> and dyslipidemia</article-title><source><italic>Biochimica et Biophysica Acta</italic></source><year>2007</year><volume>1771</volume><issue>8</issue><fpage>961</fpage><lpage>971</lpage><pub-id pub-id-type="pmid">17604218</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zoete</surname><given-names>V</given-names></name><name><surname>Grosdidier</surname><given-names>A</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators</article-title><source><italic>Biochimica et Biophysica Acta</italic></source><year>2007</year><volume>1771</volume><issue>8</issue><fpage>915</fpage><lpage>925</lpage><pub-id pub-id-type="pmid">17317294</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>MH</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>P</given-names></name><name><surname>Husna</surname><given-names>B</given-names></name><name><surname>Tai</surname><given-names>ES</given-names></name><name><surname>Yong</surname><given-names>EL</given-names></name></person-group><article-title>A natural polymorphism in peroxisome proliferator-activated receptor-<italic>&#x003b1;</italic> hinge region attenuates transcription due to defective release of nuclear receptor corepressor from chromatin</article-title><source><italic>Molecular Endocrinology</italic></source><year>2008</year><volume>22</volume><issue>5</issue><fpage>1078</fpage><lpage>1092</lpage><pub-id pub-id-type="pmid">18292238</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caron-Dorval</surname><given-names>D</given-names></name><name><surname>Paquet</surname><given-names>P</given-names></name><name><surname>Paradis</surname><given-names>A-M</given-names></name><etal/></person-group><article-title>Effect of the PPAR-alpha L162V polymorphism on the cardiovascular disease risk factor in response to <italic>n</italic>-3 polyunsaturated fatty acids</article-title><source><italic>Journal of Nutrigenetics and Nutrigenomics</italic></source><year>2008</year><volume>1</volume><issue>4</issue><fpage>205</fpage><lpage>212</lpage></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balk</surname><given-names>EM</given-names></name><name><surname>Lichtenstein</surname><given-names>AH</given-names></name><name><surname>Chung</surname><given-names>M</given-names></name><name><surname>Kupelnick</surname><given-names>B</given-names></name><name><surname>Chew</surname><given-names>P</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name></person-group><article-title>Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review</article-title><source><italic>Atherosclerosis</italic></source><year>2006</year><volume>189</volume><issue>1</issue><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">16530201</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>WS</given-names></name></person-group><article-title>n-3 fatty acids and serum lipoproteins: human studies</article-title><source><italic>American Journal of Clinical Nutrition</italic></source><year>1997</year><volume>65</volume><issue>5</issue><fpage>1645S</fpage><lpage>1654S</lpage><pub-id pub-id-type="pmid">9129504</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>S-H</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name><name><surname>Marsh</surname><given-names>JB</given-names></name></person-group><article-title>Effects of eicosapentaenoic and docosahexaenoic acids on apoprotein B mRNA and secretion of very low density lipoprotein in HepG2 cells</article-title><source><italic>Arteriosclerosis</italic></source><year>1989</year><volume>9</volume><issue>6</issue><fpage>836</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">2556098</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobatake</surname><given-names>Y</given-names></name><name><surname>Kuroda</surname><given-names>K</given-names></name><name><surname>Jinnouchi</surname><given-names>H</given-names></name></person-group><article-title>Differential effects of dietary eicosapentaenoic and docosahexaenoic fatty acids on lowering of triglyceride and cholesterol levels in the serum of rats on hypercholesterolemic diet</article-title><source><italic>Journal of Nutritional Science and Vitaminology</italic></source><year>1984</year><volume>30</volume><issue>4</issue><fpage>357</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">6096527</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willumsen</surname><given-names>N</given-names></name><name><surname>Hexeberg</surname><given-names>S</given-names></name><name><surname>Skorve</surname><given-names>J</given-names></name><name><surname>Lundquist</surname><given-names>M</given-names></name><name><surname>Berge</surname><given-names>RK</given-names></name></person-group><article-title>Docosahexaenoic acid shows no triglyceride-lowering effects but increases the peroxisomal fatty acid oxidation in liver of rats</article-title><source><italic>Journal of Lipid Research</italic></source><year>1993</year><volume>34</volume><issue>1</issue><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">8445337</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>I</given-names></name><name><surname>Wakamatsu</surname><given-names>K</given-names></name><name><surname>Inayoshi</surname><given-names>A</given-names></name><name><surname>Imaizumi</surname><given-names>K</given-names></name><name><surname>Sugano</surname><given-names>M</given-names></name><name><surname>Yazawa</surname><given-names>K</given-names></name></person-group><article-title>						<italic>&#x003b1;</italic>-linolenic, eicosapentaenoic and docosahexaenoic acids affect lipid metabolism differently in rats</article-title><source><italic>Journal of Nutrition</italic></source><year>1994</year><volume>124</volume><issue>10</issue><fpage>1898</fpage><lpage>1906</lpage><pub-id pub-id-type="pmid">7931698</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>I</given-names></name><name><surname>Cha</surname><given-names>J-Y</given-names></name><name><surname>Yanagita</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effects of dietary <italic>&#x003b1;</italic>-linolenic, eicosapentaenoic and docosahexaenoic acids on hepatic lipogenesis and <italic>&#x003b2;</italic>-oxidation in rats</article-title><source><italic>Bioscience, Biotechnology and Biochemistry</italic></source><year>1998</year><volume>62</volume><issue>4</issue><fpage>675</fpage><lpage>680</lpage></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rambj&#x000f8;r</surname><given-names>GS</given-names></name><name><surname>W&#x000e5;len</surname><given-names>AI</given-names></name><name><surname>Windsor</surname><given-names>SL</given-names></name><name><surname>Harris</surname><given-names>WS</given-names></name></person-group><article-title>Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans</article-title><source><italic>Lipids</italic></source><year>1996</year><volume>31</volume><issue>1</issue><fpage>S45</fpage><lpage>S49</lpage><pub-id pub-id-type="pmid">8729093</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grimsgaard</surname><given-names>S</given-names></name><name><surname>B&#x000f8;naa</surname><given-names>KH</given-names></name><name><surname>Hansen</surname><given-names>J-B</given-names></name><name><surname>Nord&#x000f8;y</surname><given-names>A</given-names></name></person-group><article-title>Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids</article-title><source><italic>American Journal of Clinical Nutrition</italic></source><year>1997</year><volume>66</volume><issue>3</issue><fpage>649</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">9280188</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanderson</surname><given-names>LM</given-names></name><name><surname>de Groot</surname><given-names>PJ</given-names></name><name><surname>Hooiveld</surname><given-names>GJEJ</given-names></name><etal/></person-group><article-title>Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics</article-title><source><italic>PLoS ONE</italic></source><year>2008</year><volume>3</volume><issue>2</issue><fpage>p. e1681</fpage></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Vogel-van den Bosch</surname><given-names>HM</given-names></name><name><surname>B&#x000fc;nger</surname><given-names>M</given-names></name><name><surname>de Groot</surname><given-names>PJ</given-names></name><name><surname>Bosch-Vermeulen</surname><given-names>H</given-names></name><name><surname>Hooiveld</surname><given-names>GJEJ</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name></person-group><article-title>PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression</article-title><source><italic>BMC Genomics</italic></source><year>2008</year><volume>9, article 231</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">18171476</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Transcriptionalactivity by L162-PPAR<italic>&#x003b1;</italic> and V162-PPAR<italic>&#x003b1;</italic>in HepG2 cells supplemented with EPA, DHA, and mixtures of EPA:DHA. The DR1-PPRE-TKpGL3reporter construct (100 ng) was cotransfected with the pRL-NULL plasmid (30 ng)in HepG2 cells in presence of 10 ng pSG5-hPPAR<italic>&#x003b1;</italic> wild-type (black bars) or mutated (white bars)and pSG5-mRXR<italic>&#x003b1;</italic>(10 ng) plasmids. Cells were subsequently treated or not with ciprofibrate (250 <italic>&#x003bc;</italic>M) or varying concentrations and mixtures of EPA and/or DHA for 24 hours. Values were normalizedto internal Renilla luciferase activity as described in materials and methodsand expressed as fold-induction relative to the control (TK-pGL3) set at 1. Values are representative of 2 independent experiments realized in triplicates.</p></caption><graphic xlink:href="PPAR2009-369602.001"/></fig></floats-wrap></article>